Custom ablation laser technology is now available! What does that mean for you? It means that you may be able to see better after laser surgery than you ever could--even with your glasses or contact lenses! The FDA trials FOR THIS NEW PROCEDURE showed that 40% of patients saw better after laser surgery than they did prior to surgery-- even with their glasses or contacts!
How is this possible? Traditional laser treatment for vision correction treats everyone the same, averaging the correctable prescription in your glasses or contacts. In fact, however, no two eyes are really exactly the same- so "averages" are slightly off for most people. The new laser measures every eye independently and treats the EXACT correction for that eye, alone. This allows for more accuracy on a per person basis, leading to the improved visions!!!
This technology can also be used to correct minor defects or
Symptoms from PRIOR PRK, LASIK,or RK, as well!!
If you are looking for the newest and most accurate laser surgery to correct your vison or you have some problems with your prior refractive surgery, this new technology may be what you?ve been waiting for. CALL 602-258-7101 NOW, FOR A FREE SCREENING.


VISX CustomVue Laser Vision Correction Procedure Approved by the FDA

First Custom Ablation Approval for Nearsightedness and Astigmatism

SANTA CLARA, CALIFORNIA, May 23, 2003 ? VISX, INCORPORATED (NYSE Symbol: EYE) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VISX CustomVue laser vision correction, a procedure that sets a new standard for vision correction, with the potential to enable better vision than contacts or glasses.

The CustomVue procedure tailors a unique correction for each individual. It employs the VISX WaveScan System, a new diagnostic system that captures a "fingerprint" of the eye which is 25 times more precise than what was previously measurable by standard methods. WaveScan evaluates more than nearsightedness, farsightedness, and astigmatism; it captures other, more specific imperfections in each individual's vision. This data is then used to generate an individualized treatment for a CustomVue procedure.

Dr. Robert Maloney, Director of the Maloney Vision Institute and Associate Clinical Professor of Ophthalmology, UCLA School of Medicine, participated in the VISX multi-center clinical study. Dr Maloney stated, "The results from CustomVue procedures are very impressive, with potential for sharper vision and improved night vision over contacts and glasses. There is no question that this technology is a significant step forward in the advancement of laser vision correction."

The VISX clinical study results that were the basis of the Company's FDA approval exceeded all of the FDA required measurements for safe and effective laser vision correction. The FDA approval allows for WaveScan diagnosis and CustomVue treatment of patients with nearsightedness and astigmatism.

Clinical data presented at the American Society of Cataract and Refractive Surgery 2003 Symposium and Congress in San Francisco showed that at one year following the procedure, all of the follow-up examinations indicated that participants could pass a driving test to drive without glasses or contacts. 94% of the participants could see 20/20 or better and nearly 70% could see better than 20/20 without glasses or contacts. A six-month evaluation of clinical study participants showed that four times as many people were very satisfied with their night vision after the VISX CustomVue procedure, compared to their night vision before with glasses or contacts.

"Our goal is to continue to introduce new technologies that advance laser vision correction. We are very pleased to be the first on the U.S. market with approval of laser vision correction for both nearsightedness and astigmatism. We are now moving ahead with an FDA approved human clinical study for CustomVue procedures for the treatment of farsightedness," stated Liz Dávila, chairman and chief executive officer of VISX.

About the market for Laser Vision Correction: It is estimated that in the U.S. alone, there are 50 to 60 million people that are good candidates for laser vision correction. The majority of these people require vision correction for myopia and astigmatism.

About VISX: VISX is a worldwide market leader in the design, manufacture, and sale of laser vision correction systems. Ophthalmologists have performed over 5 million procedures using VISX Systems, reducing or eliminating completely the need for contacts or glasses. Additional information on VISX and VISX trained and certified ophthalmologists can be found on the worldwide web at